NKF to invest $95m in US generic injectables company Meitheal
Pharma acquisition news : Hong Kong King-Friend Industrial Company, a subsidiary of Chinese manufacturer Nanjing King-Friend Biochemical Pharmaceutical Company (NKF), has agreed to increase its stake in US generic injectables company Meitheal Pharmaceuticals for $95 million. Following the completion of the transaction, which is likely to be in Q4 2019, NKF will have a majority stake […]
The post NKF to invest $95m in US generic injectables company Meitheal appeared first on PharmaNewsDaily.com.
Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS
Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]
The post Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS appeared first on PharmaNewsDaily.com.
Boston Scientific to be distributor of Endologix products in China
US medical devices company Endologix, which develops minimally invasive treatments for aortic disorders, signed an agreement with medical devices manufacturer Boston Scientific under which the latter becomes the exclusive distributor for its products in China. The long-term agreement covers distribution rights to Endologix’s EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, and also […]
The post Boston Scientific to be distributor of Endologix products in China appeared first on PharmaNewsDaily.com.
Gilead Sciences announces Biktarvy China approval for HIV-1
Biktarvy China approval : US biopharma company Gilead Sciences said that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection. The once-daily single tablet regimen (STR) Biktarvy is a combination of the unboosted integrase strand transfer inhibitor (INSTI) bictegravir and the dual […]
The post Gilead Sciences announces Biktarvy China approval for HIV-1 appeared first on PharmaNewsDaily.com.
ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs
US oncology company ORIC Pharmaceuticals has raised $55 million through a Series D financing round to advance its pipeline of cancer resistance drugs, as per the latest pharma industry news. The financing brings the total capital raised by the San Fransisco-based ORIC Pharmaceuticals to more than $175 million. Leading the Series D financing round of the […]
The post ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs appeared first on PharmaNewsDaily.com.
Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation
Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation
French pharma company Dynacure has secured orphan drug designation for its investigational antisense drug DYN101 from the US Food and Drug Administration (FDA) for the treatment of Centronuclear Myopathies (CNM). DYN101, which is designed to modulate the expression of dynamin 2 (DNM2), will undergo its first human clinical trial in the form of the Unite-CNM […]
The post Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation appeared first on PharmaNewsDaily.com.
Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector
Windgap Medical has forged a partnership with ALK-Abello to commercialize the former’s epinephrine autoinjector (EAI) for the treatment of anaphylactic shock. As per the agreement, ALK-Abello will have exclusive, worldwide sales and distribution rights for the Windgap epinephrine autoinjector. For this, ALK-Abello will be making up-front, technical, and sales milestone payments plus tiered royalties on […]
The post Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector appeared first on PharmaNewsDaily.com.
89bio begins phase 1b/2a NASH clinical trial of BIO89-100
BIO89-100 NASH clinical trial : US-based biopharma company 89Bio has initiated a proof of concept phase 1b/2a clinical trial for BIO89-100, its NASH drug in development, by screening the first patients. The proof of concept trial will evaluate the glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in patients with nonalcoholic steatohepatitis (NASH) or patients […]
The post 89bio begins phase 1b/2a NASH clinical trial of BIO89-100 appeared first on PharmaNewsDaily.com.
Permira Funds to acquire US CDMO Cambrex for $2.4bn
Permira acquisition of Cambrex : Global investment firm Permira Funds, through one of its affiliates, has agreed to acquire US contract development and manufacturing organization (US CDMO) Cambrex for about $2.4 billion, including the assumption of its net debt. Based in New Jersey, Cambrex is a small molecule company that offers drug substance, drug product, and […]
The post Permira Funds to acquire US CDMO Cambrex for $2.4bn appeared first on PharmaNewsDaily.com.